More Diabetes-Associated, Non-Associated Autoantibodies in T1D

Share this content:
More Diabetes-Associated, Non-Associated Autoantibodies in T1D
More Diabetes-Associated, Non-Associated Autoantibodies in T1D

TUESDAY, Sept. 6, 2016 (HealthDay News) -- Patients with type 1 diabetes have more diabetes-associated autoantibodies (DAAs) and non-DAAs than patients with type 2 diabetes, according to a study published online Aug. 29 in Diabetes Care.

Nanette C. Schloot, M.D., from Heinrich-Heine University in Düsseldorf, Germany, and colleagues analyzed patients with adult-onset type 1 diabetes (80 patients: 50 with latent autoimmune diabetes in adults [LADA] and 30 with classic type 1 diabetes) and type 2 diabetes (626 patients) for DAAs (GAD antibody [GADA], IA-2 antigen, islet cell antibody, and zinc transporter T8), non-DAAs (transglutaminase, thyroid peroxide autoantibodies, parietal cell antibodies), and concentrations of 10 immune mediators.

The researchers found that patients with type 1 diabetes (LADA or classic) could not be differentiated by autoantibodies or immune mediators. Nine of 10 immune mediators were negatively correlated with DAA titers in type 1 diabetes. Type 2 patients had no DAAs and had fewer non-DAAs (P < 0.0005), but had higher levels of proinflammatory immune mediators, especially compared to patients with type 1 diabetes who had high GADA titers.

"Differences in the clinical classification of diabetes are associated with graded differences in adaptive and innate immune reactivity," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry; the study was partially funded by DeveloGen.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Extended-Release Naltrexone Promising for Opioid Dependence

Extended-Release Naltrexone Promising for Opioid Dependence

Lower use of heroin, other illicit opioids with extended-release naltrexone in superiority analysis

New Expert Consensus Pathway for Mitral Regurgitation

New Expert Consensus Pathway for Mitral Regurgitation

Etiology, mechanism, severity, indications for treatment should be assessed after MR is identified

Many Dermatology Guideline Authors Get Industry Payments

Many Dermatology Guideline Authors Get Industry Payments

22 of 40 guideline authors receiving payments did not accurately disclose industry relationships

is free, fast, and customized just for you!

Already a member?

Sign In Now »